Old Web
English
Sign In
Acemap
>
authorDetail
>
Dongyue Fu
Dongyue Fu
AstraZeneca
Internal medicine
Oncology
Bevacizumab
Medicine
Lung cancer
2
Papers
2
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC).
2021
BioDrugs
Konstantinos N. Syrigos
Istvan Abert
Z. Andrić
Igor Bondarenko
Mikhail Dvorkin
Kristina Galic
Rinat Galiulin
Vladimer Kuchava
Virote Sriuranpong
Dmytro Trukhin
Edvard Zhavrid
Dongyue Fu
Laurent M Kassalow
Stephanie Jones
Zahid Bashir
Avana Investigators
Show All
Source
Cite
Save
Citations (1)
Efficacy and safety of bevacizumab biosimilar FKB238 versus originator bevacizumab: Results from a phase III trial in patients with non-squamous non-small cell lung cancer (NS-NSCLC).
2020
Journal of Clinical Oncology
Konstantinos N. Syrigos
Dongyue Fu
Stephanie Jones
Zahid Bashir
Show All
Source
Cite
Save
Citations (1)
1